Classical complement pathway factor alterations in narcolepsy

• Published in: Acta neuropsychiatrica Vol. 34; no. 4; pp. 1 - 219
• Main Authors: Yüceer, Hande, Gezen Ak, Duygu, Benbir Şenel, Gülçin, Dursun, Erdinç, Yılmaz, Vuslat, Karadeniz, Derya, Tüzün, Erdem, Küçükali, Cem İsmail
• Format: Journal Article
• Language: English; Dutch
• Published: England Cambridge University Press 01.08.2022
• Subjects: Antibodies; Body mass index; Disease; Eye movements; Sleep disorders; Strain gauges; United States > US; Pittsburgh Pennsylvania; complement system proteins; autoimmunity; complement C4b-binding protein; narcolepsy; complement C1q
• ISSN: 0924-2708; 1601-5215
• DOI: 10.1017/neu.2021.42

Narcolepsy is a chronic sleep disorder long hypothesised to be an autoimmune disease. Complement-mediated immune mechanisms have not been investigated in detail in narcolepsy. Our aim was to establish the significance of classical pathway activation in narcolepsy. Sera of 42 narcolepsy patients and 26 healthy controls were screened with ELISA to determine the levels of C1q, C3a, C4d and complement component 4 binding protein (C4BP). A home-made ELISA method was developed to detect antibodies to C4BP-alpha (anti-C4BPA). The correlation between complement levels and clinical findings was examined. C1q levels were significantly higher in narcolepsy patients while C4d and C4BP levels were significantly lower compared to healthy controls. C3a levels were comparable among patients and controls. Eleven narcolepsy patients showed serum anti-C4BPA levels. Total rapid eye movements (REM) time, sleep onset latency, REM sleep latency, sleep activity, percentage of wakefulness after sleep onset and Epworth sleepiness scale scores were correlated with levels of different complement factors. Complement-mediated immune mechanisms might partake in narcolepsy pathogenesis. The precise role of autoantibodies on complement level alterations needs to be investigated. Levels of complement factors and degradation products may potentially be utilised as biomarkers to predict the clinical severity of narcolepsy.